Rezolute (RZLT) announced the appointment of Erik Harris to its Board of Directors, effective immediately. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx (RARE), brings more than 20 years of biopharmaceutical expertise to Rezolute.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute’s Strategic Advances in Rare Disease Therapies
- Rezolute’s Promising Clinical Trials and Robust Financials Justify ‘Buy’ Rating
- Rezolute to announce DMC conclusions in April, says H.C. Wainwright
- Rezolute price target raised to $9 from $8 at JMP Securities
- Rezolute reports Q2 EPS (22c), consensus (26c)